BLA 761083 · Genentech INC
Hemlibra
Emicizumab · Injection
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Nov 16, 2017
Approved uses
3
Original approval plus efficacy supplements
Registered trials
36
19 Phase 3, 10 recruiting
FAERS reports
12,873
4,932 serious, 416 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: THROMBOTIC MICROANGIOPATHY AND THROMBOEMBOLISM Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur. WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM See full prescribing information for complete boxed warning. Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of...
What it is approved for
From the label in effect Jul 11, 2025.
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. ( 1 )
Mechanism: HEMLIBRA bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 4, 2018 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Oct 4, 2018 Supplement 2 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 16, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
4 products under this application
- HEMLIBRA · EMICIZUMAB 60MG/0.4ML · INJECTABLE, INJECTION · Prescription
- HEMLIBRA · EMICIZUMAB 105MG/0.7ML · INJECTABLE, INJECTION · Prescription
- HEMLIBRA · EMICIZUMAB 30MG/ML · INJECTABLE, INJECTION · Prescription
- HEMLIBRA · EMICIZUMAB 150MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Emicizumab" as an intervention, any sponsor and status, largest first.
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia APivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07416604 · 360 participants (planned) · Start Apr 27, 2026 · Primary completion Feb 29, 2028
Drug: Emicizumab · For: Hemophilia A
Sites: Orange, California; Aurora, Colorado; Miami, Florida · 63 sites in all
- A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With InhibitorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03191799 · 195 participants · Start Sep 5, 2017 · Primary completion Nov 19, 2020
Drug: Emicizumab · For: Hemophilia A
Sites: Camperdown, Australia; Melbourne, Australia; Murdoch, Australia · 72 sites in all
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without InhibitorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02847637 · 152 participants · Start Sep 27, 2016 · Primary completion Sep 15, 2017
Drug: Emicizumab; Factor VIII (FVIII) · For: Hemophilia A
Sites: Santa Monica, California; Washington D.C., District of Columbia; Gainesville, Florida · 39 sites in all
- A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05181618 · 136 participants · Start Jun 20, 2022 · Primary completion Nov 19, 2026
Drug: Emicizumab · For: Severe Hemophilia A; Moderate Hemophilia A
Sites: Miami, Florida; Oklahoma City, Oklahoma; Campinas, Brazil · 26 sites in all
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With InhibitorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02622321 · 113 participants · Start Nov 18, 2015 · Primary completion Oct 25, 2016
Drug: Emicizumab; rFVIIa and 1 more · For: Hemophilia A
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 44 sites in all
- A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) InhibitorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02795767 · 88 participants · Start Jul 22, 2016 · Primary completion Apr 30, 2018
Drug: Emicizumab · For: Hemophilia A
Sites: Los Angeles, California; Aurora, Colorado; Atlanta, Georgia · 28 sites in all
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03315455 · 85 participants · Start Apr 26, 2018 · Primary completion Aug 3, 2022
Drug: Emicizumab · For: Hemophilia A
Sites: Beijing, China; Changsha, China; Guangdong Province Guangzhou City, China · 13 sites in all
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06998524 · 75 participants (planned) · Start Jun 27, 2025 · Primary completion Oct 6, 2027
Drug: Emicizumab; von Willebrand Factor (VWF) Concentrates and 3 more · For: Von Willebrand Disease, Type 3
Sites: Sacramento, California; Gainesville, Florida; Lexington, Kentucky · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemorrhage4,767
- haemarthrosis890
- off label use826
- no adverse event812
- fall705
- arthralgia539
- epistaxis437
- contusion427
- head injury382
- pain352
- muscle haemorrhage332
- limb injury257
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2017 | 5 |
| 2018 | 159 |
| 2019 | 318 |
| 2020 | 527 |
| 2021 | 594 |
| 2022 | 973 |
| 2023 | 2,901 |
| 2024 | 3,633 |
| 2025 | 2,066 |
| 2026 | 1,696 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Hemlibra (Emicizumab-Kxwh) · HCPCS J7170
2024 spending
$230M
Beneficiaries
438
5,480 claims
Per beneficiary
$525,221
2024 ASP limit $51.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $147,878,934 |
| 2021 | $178,638,413 |
| 2022 | $203,557,787 |
| 2023 | $233,254,207 |
| 2024 | $230,046,953 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J, Mahlangu JN, Kim B, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J, Oldenburg J, Paz-Priel I, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU, Negrier C, Paz-Priel I, et al. · Blood 2021 · Clinical Trial, Phase III, Multicenter Study
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, et al. · Lancet Haematol 2019 · Clinical Trial, Phase III, Multicenter Study
- Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C, Mahlangu J, Lehle M, et al. · Lancet Haematol 2023 · Multicenter Study, Clinical Trial, Phase III
- A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants.
Sambe T, Miwa T, Yoneyama K, et al. · J Thromb Haemost 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.